Complex decisions for first-line and maintenance treatment of advanced wild-type non-small cell lung cancer

Oncologist

Volumn 20, Issue 3, 2015, Pages 299-306

  Gentzler, Ryan D ^a   Johnson, Melissa L ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

Chemotherapy; Disease management; Lung cancer; Metastatic

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; NAVELBINE; NECITUMUMAB; PACLITAXEL; PEMETREXED; PLATINUM; VASCULOTROPIN; ANTINEOPLASTIC AGENT;

ANEMIA; ARTICLE; BLEEDING; CANCER GROWTH; DISEASE COURSE; DRUG INDUCED DISEASE; FATIGUE; GENE MUTATION; HISTOLOGY; HUMAN; HYPERTENSION; HYPONATREMIA; MAINTENANCE THERAPY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; THROMBOCYTOPENIA; CARCINOMA, NON-SMALL-CELL LUNG; DECISION MAKING; LUNG NEOPLASMS;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; DECISION MAKING; HUMANS; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84925457199     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0212     Document Type: Article

References (38)

1. Park JO, Kim SW, Ahn JS et al. Phase III trialoftwo versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol 2007;25:5233–5239.
2. Hotta K, Matsuo K, Ueoka H et al. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004;22:3852–3859.
3. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92–98.
4. Subramanian J, Regenbogen T, Nagaraj G et al. Review of ongoing clinical trialsinnon-small-cell lung cancer: A status report for 2012 from the Clinical-Trials.gov web site. J Thorac Oncol 2013;8:860–865.
5. Gentzler RD, Yentz SE, Rademaker A et al. Review of 10 years of ASCO abstracts for non-small celllungcancer(NSCLC)andtheimpactofmolecular biomarkers (MB) in clinical trial selection criteria. J Thorac Oncol 2013;8:S890–S891.
6. Mok TS, Wu YL,Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarci-noma. N Engl J Med 2009;361:947–957.
7. Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versuschemotherapyinadvancedALK-positivelung cancer. N Engl J Med 2013;368:2385–2394.
8. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542–2550.
9. Ramalingam SS, Dahlberg SE, Langer CJ et al. Outcomes forelderly, advanced-stagenon small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: Analysis of Eastern Cooperative Oncology Group trial 4599. J Clin Oncol 2008;26:60–65.
10. Langer CJ, Socinski MA, Patel JD et al. Efficacy and safety of paclitaxel and carboplatin with bevacizumab for the first-line treatment of patients with non-squamous non-small cell lung cancer (NSCLC): Analyses based on age in the phase III PointBreak and E4599 trials. J Clin Oncol 2013;31(suppl):8073a.
11. Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study. Lancet 2009;374:1432–1440.
12. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543–3551.
13. Quoix E, Zalcman G, Oster JP et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011;378:1079–1088.
14. Zukin M, Barrios CH, Pereira JR et al. Randomized phase III trialofsingle-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Groupperformance status of 2. J Clin Oncol 2013;31:2849–2853.
15. Fidias PM, Dakhil SR, Lyss AP et al. Phase III study of immediate compared with delayed doce-taxel after front-line therapy with gemcitabine plus carboplatininadvanced non-small-celllung cancer. J Clin Oncol 2009;27:591–598.
16. Paz-Ares LG, de Marinis F, Dediu M et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with peme-trexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;31:2895–2902.
17. Cappuzzo F, Ciuleanu T, Stelmakh L et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomized, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521–529.
18. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362: 2380–2388.
19. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermalgrowthfactorreceptor (WJTOG3405):An open label, randomized phase 3 trial. Lancet Oncol 2010;11:121–128.
20. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multi-centre, open-label, randomized, phase 3 study. Lancet Oncol 2011;12:735–742.
21. Han JY, Park K, Kim SW et al. First-SIGNAL: First-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarci-noma of the lung. J Clin Oncol 2012;30:1122–1128.
22. Sequist LV, Yang JC, Yamamoto N et al. PhaseIII study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31: 3327–3334.
23. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 2009;373:1525–1531.
24. Lynch TJ, Patel T, Dreisbach L et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: Results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010;28:911–917.
25. Thatcher N, Hirsch FR, Szczesna A et al. A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). J Clin Oncol 2014;32(suppl):8008a.
26. Patel JD, Hensing TA, Rademaker A et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009;27: 3284–3289.
27. Barlesi F, Scherpereel A, Rittmeyer A et al. Randomized phase III trial of maintenance bevaci-zumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and peme-trexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol 2013;31:3004–3011.
28. Rittmeyer A, Scherpereel A, Gorbunova VA et al. Effect of maintenance bevacizumab (Bev) plus pemetrexed (Pem) after first-line cisplatin/ Pem/Bevinadvancednonsquamousnon-smallcell lung cancer (nsNSCLC) on overall survival (OS) of patients (pts) on the AVAPERL (MO22089) phase III randomized trial. J Clin Oncol 2013;31(suppl): 8014a.
29. Johnson BE, Kabbinavar F, Fehrenbacher L et al. ATLAS: Randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2013;31:3926–3934.
30. Patel JD, Socinski MA, Garon EB et al. Point-Break: A randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;31:4349–4357.
31. Zinner R, Ross HJ, Weaver R et al. Randomized, open-label, phase III study of pemetrexed plus carboplatin (PemC) followed bymaintenance peme-trexed versus paclitaxel/carboplatin/bevacizumab (PCB) followed by maintenance bevacizumab in patients with advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). J Clin Oncol 2013;31 (suppl):LBA8003a.
32. Patel JD, Socinski MA, Garon EB et al. A randomized, open-label, phase 3, superiority study of pemetrexed (Pem)1carboplatin (Cb)1bevacizu-mab (B) followed by maintenance Pem1B versus paclitaxel (Pac)1Cb1B followed by maintenance B in patients (pts) with stage IIIb or IV non-squamous non-small cell lung cancer (ns-NSCLC). J Thorac Oncol 2012;7:S336–S338[abstract LBPL331].
33. Socinski MA, Bondarenko I, Karaseva NA et al. Weekly nab-paclitaxel in combination with carbo-platin versus solvent-based paclitaxel plus carbo-platin as first-line therapy in patients with advanced non-small-cell lung cancer: Final resultsofaphase III trial. J Clin Oncol 2012;30:2055–2062.
34. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevaci-zumab plus carboplatin and paclitaxel with carbo-platin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191.
35. Dahlberg SE, Ramalingam SS, Belani CP et al. A randomized phase III study of maintenance therapy with bevacizumab (B), pemetrexed (Pm), or a combination of bevacizumab and pemetrexed (BPm) following carboplatin, paclitaxel and bevacizumab (PCB) for advanced nonsquamous NSCLC: ECOG trial 5508 (NCT01107626). J Clin Oncol 2011;29(suppl):TPS218a.
36. Perol M, Chouaid C, Perol D et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2012;30: 3516-3524.
37. Brodowicz T, Krzakowski M, Zwitter M et al. Cisplatin and gemcitabine first-line chemotherapy S followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer 2006;52: 155-163.
38. NCCN clinical practice guidelines in oncology (NCCN Guidelines). Non-small cell lung cancer (version 3.2014). Available at http://www.nccn.org/professionals/physician_gls/pdf/ nscl.pdf. Accessed April 24, 2014.